Received Jul 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2G273 | LA |
patient was suppose to boostrix but was administered with Pediarix in error; patient was supposed to boostrix but was administered with Pediarix in error; This non-serious case was reported by a nurse via sales rep and described the occurrence of wrong vaccine administered in a 10-year-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number 2G273, expiry date 15-APR-2027) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On 10-JUN-2025, the patient received Pediarix (left deltoid). On an unknown date, the patient did not receive Boostrix. On 10-JUN-2025, immediately after receiving Pediarix and not applicable after receiving Boostrix, the patient experienced wrong vaccine administered (Verbatim: patient was suppose to boostrix but was administered with Pediarix in error) and inappropriate age at vaccine administration (Verbatim: patient was supposed to boostrix but was administered with Pediarix in error). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:01-JUL-2025 The reporter HCP found out about it when they were doing their audit. The patient was supposed to Boostrix but was administered with Pediarix in error and no symptoms had been reported by the patient. The patient wanted to get it as a prevention but instead of Boostrix, Pediarix was administered in error, which led to wrong vaccine administered and inappropriate age at vaccine administration.